NDC product
VARIVAX
NDC 0006-4827 · Merck Sharp & Dohme LLC
Key facts
| Product NDC | 0006-4827 |
|---|---|
| Proprietary name | VARIVAX |
| Nonproprietary name | Varicella Virus Vaccine Live |
| Substances | VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION |
| Route | SUBCUTANEOUS |
| Labeler | Merck Sharp & Dohme LLC |
| Product type | VACCINE |
| Marketing category | BLA |
| Application number | BLA103552 |
| Pharmacologic classes | Actively Acquired Immunity [PE], Chickenpox Vaccine [CS], Herpes Zoster Vaccine [CS], Live Attenuated Herpes Zoster Virus Vaccine [EPC], Live Attenuated Varicella Zoster Virus Vaccine [EPC], Vaccines and 1 more |
| Marketing start | Mar 17, 1995 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: